ArticleHead & neck2026
Radiofrequency Ablation of Low-Risk Primary Papillary Thyroid Carcinoma in a Clinic Setting.
Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRadiofrequency ablation (RFA) is a minimally invasive alternative to thyroidectomy for select thyroid pathologies. Although international data support its safety and efficacy for small papillary thyroid carcinoma (PTC), U.S. data is limited. This study evaluates outpatient RFA outcomes for biopsy-confirmed low-risk PTC performed in a clinic setting with local anesthesia only.
methodsA retrospective review was conducted of adults who underwent outpatient RFA for PTC between September 2021 and February 2025. Nodules were confined to the thyroid gland without nodal or distant metastasis. Nodule volume reduction rate (VRR), thyroid function, delivered energy, and complications were analyzed.
resultsSeventeen RFA procedures were performed on 15 nodules. Baseline median volume and maximum diameter were 0.41 mL and 1.10 cm, respectively, and average VRR reached 85.3% at 12 months. Two transient complications occurred, and thyroid function remained stable.
conclusionsClinic-performed RFA for small, low-risk PTC is safe, effective, and preserves thyroid function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.